Account
Insider Insights
13.06.2023
Collaboration proposes a new method for combinatio...

In a joint report Lif, the New Therapeutics (NT) Council and representatives of the regions have pro...

Read more
Insider Insights
27.07.2022
Macmillan alliance will provide digital health app

According to Big health, randomised controlled trials have shown that 71% of patients who used Dayli...

Read more
Insider Insights
21.03.2022
Early access agreement

Patients in England will be the first in Europe to have access to Takeda’s Exkivity (mobocertinib)...

Read more
Articles
16.03.2022
The impacts of Market Access combination pricing

We explore why combination pricing is an issue in the oncology space and why payers and manufacturer...

Read more
Articles
25.01.2022
PMA Perspectives Q1 2022

We hope you’ve had a wonderful start to the New Year and we’d love to welcome you to our fourth ...

Read more
Articles
08.11.2021
High cost oncology combination therapy

The use of combination therapy is increasingly becoming the standard of care in oncology as cancers ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch